Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 13, 2018 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
February 08, 2018 16:10 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
January 29, 2018 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Announces Closing of Upsized Public Offering

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced today the closing of its upsized public offering of 5,897,435 shares of its...
January 25, 2018 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
January 25, 2018 08:00 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), announced today the pricing of an underwritten public offering of 5,128,205 shares of its...
January 23, 2018 16:01 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative...
January 08, 2018 08:30 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time

Milestone for antibody targeting TIM-3 triggers $5 million payment to Five Prime BMS extends research collaboration term for discovery, development and commercialization for therapeutics in three...
January 03, 2018 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
January 03, 2018 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...
January 02, 2018 16:05 ET | Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer

SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein...